These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24919804)

  • 1. B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL).
    Petersen DL; Krejsgaard T; Berthelsen J; Fredholm S; Willerslev-Olsen A; Sibbesen NA; Bonefeld CM; Andersen MH; Francavilla C; Olsen JV; Hu T; Zhang M; Wasik MA; Geisler C; Woetmann A; Odum N
    Leukemia; 2014 Oct; 28(10):2109-12. PubMed ID: 24919804
    [No Abstract]   [Full Text] [Related]  

  • 2. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma.
    Krejsgaard T; Vetter-Kauczok CS; Woetmann A; Kneitz H; Eriksen KW; Lovato P; Zhang Q; Wasik MA; Geisler C; Ralfkiaer E; Becker JC; Ødum N
    Blood; 2009 Jun; 113(23):5896-904. PubMed ID: 19351960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel BLK-induced tumor model.
    Petersen DL; Berthelsen J; Willerslev-Olsen A; Fredholm S; Dabelsteen S; Bonefeld CM; Geisler C; Woetmann A
    Tumour Biol; 2017 Jul; 39(7):1010428317714196. PubMed ID: 28670978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
    Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
    Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
    Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT
    J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.
    Du J; Bernasconi P; Clauser KR; Mani DR; Finn SP; Beroukhim R; Burns M; Julian B; Peng XP; Hieronymus H; Maglathlin RL; Lewis TA; Liau LM; Nghiemphu P; Mellinghoff IK; Louis DN; Loda M; Carr SA; Kung AL; Golub TR
    Nat Biotechnol; 2009 Jan; 27(1):77-83. PubMed ID: 19098899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
    Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
    Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
    Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
    Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
    Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G
    Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.
    Yang C; Lu P; Lee FY; Chadburn A; Barrientos JC; Leonard JP; Ye F; Zhang D; Knowles DM; Wang YL
    Leukemia; 2008 Sep; 22(9):1755-66. PubMed ID: 18596745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
    Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
    J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
    Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ
    Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
    Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
    Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
    Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
    Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.